SAFETY DATA SHEET

SECTION 1 : IDENTIFICATION

<table>
<thead>
<tr>
<th>Product Name:</th>
<th>Tobramycin for Injection, USP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manufacturer Name:</td>
<td>Fresenius Kabi USA, LLC</td>
</tr>
<tr>
<td>Address:</td>
<td>Three Corporate Drive</td>
</tr>
<tr>
<td></td>
<td>Lake Zurich, Illinois 60047</td>
</tr>
<tr>
<td>General Phone Number:</td>
<td>(847) 550-2300</td>
</tr>
<tr>
<td>Customer Service Phone Number:</td>
<td>(888) 386-1300</td>
</tr>
<tr>
<td>Health Issues Information:</td>
<td>(800) 551-7176</td>
</tr>
<tr>
<td>SDS Creation Date:</td>
<td>January 08, 2009</td>
</tr>
<tr>
<td>SDS Revision Date:</td>
<td>June 01, 2015</td>
</tr>
</tbody>
</table>

SECTION 2 : HAZARD(S) IDENTIFICATION

GHS Pictograms:

Signal Word: DANGER.

GHS Class:
- Serious Eye Damage, Category 1.
- Skin corrosion, Category 1.
- Respiratory sensitisation, Category 1.
- Reproductive toxicity, Category 1A.
- Skin Sensitization, Category 1.
- Reproductive toxicity, Effects on or via lactation.

Hazard Statements:
- Causes serious eye damage.
- Causes severe skin burns and eye damage.
- May cause allergy or asthma symptoms or breathing difficulties if inhaled.
- May damage fertility or the unborn child.
- May cause an allergic skin reaction.
- May cause harm to breast-fed children.

Precautionary Statements:
- Obtain special instructions before use.
- Do not handle until all safety precautions have been read and understood.
- Do not breathe dust/fume/gas/mist/vapours/spray.
- Avoid breathing dust/fume/gas/mist/vapours/spray.
- Avoid contact during pregnancy and while nursing.
- Wash hands thoroughly after handling.
- Do not eat, drink or smoke when using this product.
- Contaminated work clothing should not be allowed out of the workplace.
- Wear protective gloves/protective clothing/eye protection/face protection.
- In case of inadequate ventilation wear respiratory protection.
- IF SWALLOWED: Rinse mouth. Do not induce vomiting.
- IF ON SKIN: Wash with plenty of water. If on skin (or hair): Remove/Take off immediately all contaminated clothing. Rinse skin with water/shower.
- IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing. If INHALED: Remove victim from exposure environment. If IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
- IF exposed or concerned: Get medical advice/attention.
- If skin irritation or rash occurs: Get medical advice/attention.
- If experiencing respiratory symptoms: Call a POISON CENTER or doctor/physician.
- Take off contaminated clothing and wash it before reuse.
- Wash contaminated clothing before reuse.
- Store locked up.
- Dispose of contents/container in accordance with Local, State, Federal and Provincial regulations.

Emergency Overview:
This product is intended for therapeutic use only when prescribed by a physician. Potential adverse reactions from prescribed doses and overdoses are described in the package insert.

Route of Exposure:
- Inhalation
- Ingestion
- Eye contact
- Skin Absorption
- Injection

Potential Health Effects:

Eye:
- Contact with eyes may cause irritation.

Signs/Symptoms:
- Potential adverse reactions from prescribed doses and overdoses are described in the package insert.
- The severity of the signs and symptoms following a tobramycin overdose are dependent of the dose administered, the patient's renal function, state of hydration, and age and whether or not other medications with similar toxicities are being administered concurrently. Therapeutic side effects include neurotoxicity (auditory and vestibular ototoxicity), nephrotoxicity, hematologic toxicity (anemia, granulocytopenia, etc) and laboratory abnormalities. Occupational exposure has not been fully investigated.

Aggravation of Pre-Existing Conditions:
- Individuals with a history of previous hypersensitivity or toxic reaction to any aminoglycoside. This product contains sodium metabisulfite, a sulfite that may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. Concurrent and sequential use of other neurotoxic and/or nephrotoxic antibiotics particularly other aminoglycosides (amikacin, gentamicin, etc) polymyxin B, colistin, cispatin, and vancomycin, should be avoided. Other factors that may increase risk are advanced age and dehydration.
SECTION 3 : COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Chemical Name</th>
<th>CAS#</th>
<th>Ingredient Percent</th>
<th>EC Num.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tobramycin Sulfate</td>
<td>32986-56-4</td>
<td>1.2 gm/vial</td>
<td></td>
</tr>
</tbody>
</table>

SECTION 4 : FIRST AID MEASURES

**Eye Contact:** Immediately flush eyes with plenty of water for at least 15 to 20 minutes. Ensure adequate flushing of the eyes by separating the eyelids with fingers. Get immediate medical attention.

**Skin Contact:** Immediately wash skin with plenty of soap and water for 15 to 20 minutes, while removing contaminated clothing and shoes. Get medical attention if irritation develops or persists.

**Inhalation:** If inhaled, remove to fresh air. If not breathing, give artificial respiration or give oxygen by trained personnel. Seek immediate medical attention.

**Ingestion:** If conscious, flush mouth out with water immediately. Call a physician or poison control center immediately. Do not induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious person.

**Other First Aid:** For Adverse Event Information, please call (800) 551-7176.

SECTION 5 : FIRE FIGHTING MEASURES

**Flash Point:** Not established.

**Flash Point Method:** Not established.

**Auto Ignition Temperature:** Not established.

**Lower Flammable/Explosive Limit:** Not established.

**Upper Flammable/Explosive Limit:** Not established.

**Fire Fighting Instructions:** Evacuate area of unprotected personnel. Use cold water spray to cool fire exposed containers to minimize risk of rupture. Do not enter confined fire space without full protective gear. If possible, contain fire run-off water.

**Extinguishing Media:** Use alcohol resistant foam, carbon dioxide, dry chemical, or water fog or spray when fighting fires involving this material. Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

**Protective Equipment:** As in any fire, wear Self-Contained Breathing Apparatus (SCBA), MSHA/NIOSH (approved or equivalent) and full protective gear.

**Hazardous Combustion Byproducts:** Thermal decomposition products may include smoke and toxic fumes. Oxides of carbon, oxides of nitrogen and other organic substances may be formed. Other undetermined low molecular weight hydrocarbon compounds may be released in small quantities depending upon specific conditions of combustion.

SECTION 6 : ACCIDENTAL RELEASE MEASURES

**Personnel Precautions:** Evacuate area and keep unnecessary and unprotected personnel from entering the spill area. Avoid personal contact and breathing vapors or mists. Use proper personal protective equipment as listed in Section 8.

**Environmental Precautions:** Avoid runoff into storm sewers, ditches, and waterways.

**Methods for containment:** Contain spills with an inert absorbent material such as soil, sand or oil dry.

**Methods for cleanup:** Absorb spill with inert material (e.g., dry sand or earth), then place in a chemical waste container. After removal, flush spill area with soap and water to remove trace residue.

SECTION 7 : HANDLING and STORAGE

**Handling:** When handling pharmaceutical products, avoid all contact and inhalation of vapor, mists and/or fumes. Use with adequate ventilation. Use only in accordance with directions.

**Storage:** Store at controlled room temperature 15 to 30°C (59 to 86°F).

**Work Practices:** Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower.

**Hygiene Practices:** Wash thoroughly after handling. Avoid contact with eyes and skin. Avoid inhaling vapor or mist.

SECTION 8 : EXPOSURE CONTROLS, PERSONAL PROTECTION

**Engineering Controls:** General ventilation is sufficient if this product is being used in a controlled medical setting (clinic, hospital, medical office) for its sole intended parenteral (injection) purpose. Otherwise, use appropriate engineering control such as process enclosures, local exhaust ventilation, or other engineering controls.
including use of a biosafety cabinet / fume hood to control airborne levels below recommended exposure limits.

Eye/Face Protection: Chemical splash goggles. Wear a face shield also when splash hazard exist.

Skin Protection Description: Protective laboratory coat, apron, or disposable garment recommended.

Hand Protection Description: Wear appropriate protective gloves. Consult glove manufacturer's data for permeability data. Nitrile rubber or natural rubber gloves are recommended.

Respiratory Protection: No personal respiratory protective equipment is normally required when this product is being used/administered by a licensed healthcare practitioner (i.e., an end-user such as a clinician / doctor / nurse) for its sole intended parenteral (injection) purpose in a controlled medical setting. The need for respiratory protection will vary according to the airborne concentrations and environmental conditions. A NIOSH approved air-purifying respirator with an organic vapor cartridge or canister may be permissible under certain circumstances. Consult the NIOSH web site (http://www.cdc.gov/niosh/npptl/topics/respirators/) for a list of respirator types and approved suppliers.

Other Protective: Consult with local procedures for selection, training, inspection and maintenance of the personal protective equipment.

EXPOSURE GUIDELINES

SECTION 9 : PHYSICAL and CHEMICAL PROPERTIES

<table>
<thead>
<tr>
<th>Physical State:</th>
<th>Liquid solution.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boiling Point:</td>
<td>Approximately 100°C</td>
</tr>
<tr>
<td>Melting Point:</td>
<td>Approximately 0°C</td>
</tr>
<tr>
<td>Solubility:</td>
<td>Soluble in water</td>
</tr>
<tr>
<td>Vapor Density:</td>
<td>Not established.</td>
</tr>
<tr>
<td>Vapor Pressure:</td>
<td>Not established.</td>
</tr>
<tr>
<td>Percent Volatile:</td>
<td>Not established.</td>
</tr>
<tr>
<td>pH:</td>
<td>Not established.</td>
</tr>
<tr>
<td>Molecular Formula:</td>
<td>Mixture</td>
</tr>
<tr>
<td>Molecular Weight:</td>
<td>1425.45</td>
</tr>
<tr>
<td>Flash Point:</td>
<td>Not established.</td>
</tr>
<tr>
<td>Flash Point Method:</td>
<td>Not established.</td>
</tr>
<tr>
<td>Auto Ignition Temperature:</td>
<td>Not established.</td>
</tr>
</tbody>
</table>

SECTION 10 : STABILITY and REACTIVITY

Chemical Stability: Stable under normal temperatures and pressures.

Hazardous Polymerization: Not reported.

Conditions to Avoid: No conditions contributing to instability are known to exist for normal handling of this product.

Special Decomposition Products: Thermal decomposition or burning may produce noxious products including carbon monoxide, carbon dioxide, and nitrogen oxides.

SECTION 11 : TOXICOLOGICAL INFORMATION

Tobramycin Sulfate:

Acute Toxicity:
LD50 SC Rat: 1,680 mg/kg
LD50 IV Rat: 126 mg/kg
LD50 IP Mouse: 262 mg/kg
LD50 SC Mouse: 560 mg/kg
LD50 IV Mouse: 77 mg/kg

Tobramycin Sulfate:

OSHA: Not listed
IARC: Not listed
NTP: Not listed

Tobramycin Sulfate:

RTECS Number: WX2100000

Ingestion:
Oral - Rat LD50: >7500 mg/kg [Details of toxic effects not reported other than lethal dose value]
Oral - Mouse LD50: >11500 mg/kg [Details of toxic effects not reported other than lethal dose value]

Other Toxicological Information:
Intravenous - Rat LD50: 104 mg/kg [Details of toxic effects not reported other than lethal dose value]
Intravenous - Mouse LD50: 72500 ug/kg [Behavioral - convulsions or effect on seizure threshold Behavioral - ataxia Lungs, Thorax, or Respiration - dyspnea ]
Intravenous - Mouse LD50: 70 mg/kg [Details of toxic effects not reported other than lethal dose value]
Subcutaneous - Rat LD50: 969 mg/kg [Sense Organs and Special Senses (Olfaction) - effect, not otherwise specified ]
Subcutaneous - Mouse LD50: 367 mg/kg [Sense Organs and Special Senses (Eye) - ptosis Behavioral - somnolence (general depressed activity) Lungs, Thorax, or Respiration - respiratory depression ]
Subcutaneous - Rat TDLo: 1200 mg/kg/10D-I [Kidney/Ureter/Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol)]
Subcutaneous - Rat TDLo: 560 mg/kg/14D-I [Kidney/Ureter/Bladder - other changes in urine composition]
Subcutaneous - Rat TDLo: 3250 mg/kg/65D-I [Kidney/Ureter/Bladder - other changes in urine composition (e.g. TP, bilirubin, cholesterol)]
Subcutaneous - Guinea pig TDLo: 1072 mg/kg/160-D-I [Kidney/Ureter/Bladder - other changes in urine composition (e.g. TP, bilirubin, cholesterol)]
Subcutaneous - Guinea pig TDLo: 1072 mg/kg/160-D-I [Kidney/Ureter/Bladder - other changes in urine composition (e.g. TP, bilirubin, cholesterol)]
Subcutaneous - Guinea pig TDLo: 1072 mg/kg/160-D-I [Kidney/Ureter/Bladder - other changes in urine composition (e.g. TP, bilirubin, cholesterol)]

Intraperitoneal - Rat LD50: 1030 mg/kg [Details of toxic effects not reported other than lethal dose value]
Intraperitoneal - Mouse LD50: 445 mg/kg [Details of toxic effects not reported other than lethal dose value]
Intraperitoneal - Rat TDLo: 800 mg/kg/100-D-I [Kidney/Ureter/Bladder - other changes Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - other Enzymes Biochemical - Metabolism (Intermediary) - other]
Intraperitoneal - Rat TDLo: 800 mg/kg/100-D-I [Kidney/Ureter/Bladder - other changes Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - other Enzymes Biochemical - Metabolism (Intermediary) - other]
Intraperitoneal - Rat TDLo: 800 mg/kg/100-D-I [Kidney/Ureter/Bladder - other changes Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - other Enzymes Biochemical - Metabolism (Intermediary) - other]